Trials / Unknown
UnknownNCT05610202
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
Phase I Clinical Trial of Tolerability and Pharmacokinetics of TQB3702 Tablets in Hematologic Tumor Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 137 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the tolerability and preliminary efficacy of TQB3702 tablets in hematological tumor subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3702 tablets | TQB3702 tablets are selective BTK inhibitors. |
Timeline
- Start date
- 2022-11-01
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
- First posted
- 2022-11-09
- Last updated
- 2022-11-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05610202. Inclusion in this directory is not an endorsement.